Editas Medicine, Inc.

( )
EDIT After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. 1.67%157.400.0%$1660.38m
OCGNOcugen, Inc. -8.49%10.020.0%$1166.38m
NVAXNovavax, Inc. 3.92%240.2992.9%$1037.18m
AMGNAmgen, Inc. 0.94%227.041.3%$551.89m
REGNRegeneron Pharmaceuticals, Inc. 2.77%463.052.7%$528.04m
ILMNIllumina, Inc. 1.61%446.503.5%$520.21m
VRTXVertex Pharmaceuticals, Inc. -1.02%210.381.9%$517.52m
GILDGilead Sciences, Inc. 1.73%62.461.0%$479.52m
BNGOBionano Genomics, Inc. 1.13%9.840.0%$363.69m
ALXNAlexion Pharmaceuticals, Inc. -0.51%151.972.0%$358.25m
BIIBBiogen, Inc. 0.13%273.241.7%$333.23m
CRSPCRISPR Therapeutics AG 3.63%130.250.6%$309.56m
EXASEXACT Sciences Corp. 3.01%140.2118.4%$262.38m
SGENSeagen Inc. 0.95%152.555.8%$210.49m
VXRTVaxart, Inc. 5.59%7.550.0%$209.25m

Company Profile

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.